文献速递间质性肺疾病

系统性硬化症相关进展性间质性肺病的队列富集策略:基于EUSTAR数据库的真实世界评估

Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research.
PubMed 文献 · Chest · 2022-10-14

本研究在EUSTAR数据库2258例SSc-ILD患者中应用focuSSced、SLS II和SENSCIS三项试验的入组标准,评估富集策略对进展性ILD的效力、代表性和可行性。结果显示仅31.2%符合SENSCIS标准、5.8%符合SLS II、1.6%符合focuSSced,67.7%不符合任何标准;不同标准筛选的人群临床特征差异显著,且富集标准与ILD进展无显著关联。

要点

  • 多数SSc-ILD患者(67.7%)不符合近期三大试验的入组标准,富集策略代表性有限。
  • 符合focuSSced标准的患者FVC下降更明显(-3.7%),进展者更多。
  • 富集标准与ILD进展无显著关联,且降低招募可行性。

核心结论

  • 应用既往临床试验的富集标准对进展的富集效果不一,导致筛选人群变窄并降低招募可行性。
  • 富集标准与ILD进展无显著关联,对未来试验设计和结果解读有重要意义。

研究设计与样本

  • 基于EUSTAR数据库的真实世界队列研究,共纳入2258例SSc-ILD患者。
  • 应用focuSSced、SLS II和SENSCIS三项试验的入组标准,评估进展性ILD(绝对FVC变化及FVC下降≥10%的显著进展)。

主要发现

  • 31.2%患者符合SENSCIS标准,5.8%符合SLS II标准,1.6%符合focuSSced标准,67.7%(1529例)不符合任何标准。
  • 首个12±3个月,全部患者及符合SENSCIS标准者绝对FVC下降-0.1%,符合focuSSced标准者下降-3.7%,符合SLS II标准者上升2.3%,focuSSced组进展者更多。
  • 符合不同入组标准的人群在多个临床参数上显著不同。
  • 第二个12个月,SENSCIS富集患者FVC%继续下降,而符合focuSSced和SLS II标准者肺功能数值改善。
  • 富集标准与ILD进展无显著关联。

临床怎么用

  • 解读已发表SSc-ILD试验结果时需考虑富集标准对人群选择和进展率的影响。
  • 未来试验设计应权衡富集策略的效力与招募可行性及人群代表性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Enrichment strategies from clinical trials for progressive systemic sclerosis-associated interstitial lung disease (SSc-ILD) have not been tested in a real-life cohort. RESEARCH QUESTION: Do enrichment strategies for progressive ILD impact efficacy, representativeness, and feasibility in patients with SSc-ILD from the European Scleroderma Trials and Research (EUSTAR) database? STUDY DESIGN AND METHODS: We applied the inclusion criteria of major recent SSc-ILD trials (Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis [focuSSced], Scleroderma Lung Study II [SLS II], and Safety and Efficacy of Nintedanib in Systemic Sclerosis [SENSCIS]) and assessed progressive ILD, which was defined as absolute change in FVC and as significant progression (FVC decline ≥10%). Data were compared with all patients and with patients who did not fulfill any inclusion criteria. RESULTS: In total, 2,258 patients with SSc-ILD were included: 31.2% of the patients met SENSCIS criteria; 5.8% of the patients met SLS II criteria; 1.6% of the patients met focuSSced criteria, and 67.7% (1,529) of the patients did not meet any criteria. In the first 12 ± 3 months, the absolute FVC decline in all patients and in patients who fulfilled criteria from SENSCIS was -0.1%, in patients who fulfilled criteria from focuSSced was -3.7%, and in patients who fulfilled criteria from SLS II was 2.3%, with accompanying more progressors in focuSSced. The patient populations that fulfilled the different study inclusion criteria significantly differed in various clinical parameters. In the second 12-month period, SENSCIS-enriched patients had a further absolute FVC% decline as described for the total cohort. In contrast, patients who fulfilled the focuSSced and SLS II criteria showed numeric improvement of lung function. There were no significant associations of enrichment criteria and ILD progression. INTERPRETATION: The application of enrichment criteria from previous clinical trials showed enrichment for progression with variable success, which led to selected patient populations reducing feasibility of recruitment. These findings are important for future clinical trial design and interpretation of the results of published trials.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Hoffmann-Vold AM, Brunborg C, Airò P, et al. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research. Chest. 2022. PMID: 36244404. doi:10.1016/j.chest.2022.09.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。